SCHEMBL22802440

SCHEMBL22802440

CC(C)(C)[Si](C)(C)OCc1cc(F)c(C#N)c(F)c1F

nearest known ligand 0.32

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
TRPV4 Q9HBA0 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31371936 0.88
SCHEMBL22802455 0.87 SQOR (0.33)
SCHEMBL18314460 0.81 TRPV4 (0.38) TRPV4
SCHEMBL18314383 0.76
SCHEMBL22802457 0.74 RIPK1 (0.41)
SCHEMBL29490394 0.74 RIPK1 (0.41)
SCHEMBL29490396 0.74 RIPK1 (0.41)
SCHEMBL18314346 0.74 BACE1 (0.30)
SCHEMBL29825109 0.72 MAPT (0.32)
SCHEMBL31371874 0.71 MAPT (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4741389-A1 KAT6 INHIBITOR Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) 2026-05-13 EP disclosed
US-20260062406-A1 Benzisoxazole Sulfonamide Derivatives PFIZER (US) 2026-03-05 US disclosed
EP-4299135-B1 BENZISOXAZOLE SULFONAMIDE DERIVATIVES PFIZER (US) 2025-08-06 EP disclosed
US-12371425-B2 Benzisoxazole sulfonamide derivatives PFIZER INC. (US) 2025-07-29 US disclosed
EP-3986890-B9 BENZISOXAZOLE SULFONAMIDE DERIVATIVES PFIZER (US) 2025-04-16 EP disclosed
WO-2025036382-A1 SULFONAMIDE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海复宏汉霖生物医药有限公司 2025-02-20 WO disclosed
WO-2025007873-A1 KAT6 INHIBITOR 上海齐鲁制药研究中心有限公司 2025-01-09 WO disclosed
EP-4299135-A2 BENZISOXAZOLE SULFONAMIDE DERIVATIVES Pfizer Inc. (US) 2024-01-03 EP disclosed
EP-3986890-B1 BENZISOXAZOLE SULFONAMIDE DERIVATIVES PFIZER (US) 2023-11-15 EP disclosed
EP-3986890-B1 BENZISOXAZOLE SULFONAMIDE DERIVATIVES PFIZER (US) 2023-11-15 EP disclosed
US-20230174522-A1 Benzisoxazole Sulfonamide Derivatives MONASH UNIVERSITY (AU) 2023-06-08 US disclosed
US-20230174522-A1 Benzisoxazole Sulfonamide Derivatives MONASH UNIVERSITY (AU) 2023-06-08 US disclosed
US-11492346-B2 Benzisoxazole sulfonamide derivatives PFIZER INC. (US) 2022-11-08 US disclosed
EP-3986890-A1 BENZISOXAZOLE SULFONAMIDE DERIVATIVES Pfizer Inc. (US) 2022-04-27 EP disclosed
CN-114364672-A Benzisoxazole sulfonamide derivatives 辉瑞大药厂 2022-04-15 CN disclosed
WO-2020254946-A1 BENZISOXAZOLE SULFONAMIDE DERIVATIVES PFIZER INC. (US) 2020-12-24 WO disclosed
WO-2020254946-A1 BENZISOXAZOLE SULFONAMIDE DERIVATIVES PFIZER INC. (US) 2020-12-24 WO disclosed
US-20200399258-A1 Benzisoxazole Sulfonamide Derivatives PFIZER INC. 2020-12-24 US disclosed
US-20200399258-A1 Benzisoxazole Sulfonamide Derivatives PFIZER INC. 2020-12-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12371425-B2 Benzisoxazole sulfonamide derivatives BRIX1, RB1, BCR TRPV4 2910/4885
US-20200399258-A1 Benzisoxazole Sulfonamide Derivatives BRIX1, RB1, BCR TRPV4 2837/4885
US-11492346-B2 Benzisoxazole sulfonamide derivatives BRIX1, RB1, BCR TRPV4 2910/4885
US-20260062406-A1 Benzisoxazole Sulfonamide Derivatives KAT8, KAT5, KAT7 TRPV4 3638/4885
US-20230174522-A1 Benzisoxazole Sulfonamide Derivatives BRIX1, RB1, BCR TRPV4 2910/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.